BEIJING, Nov. 20, 2024 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the third quarter ended September 30, 2024.
Third Quarter 2024 Financial Highlights
- Total revenues were RMB371.8 million (US$53.0 million[1]), compared with RMB385.3 million in the corresponding period of 2023, exceeding the high end of guidance.
- Net income attributable to So-Young International Inc. was RMB20.3 million (US$2.9 million), compared with net income attributable to So-Young International Inc. of RMB18.3 million in the same period of 2023.
- Non-GAAP net income attributable to So-Young International Inc.[2] was RMB22.2 million (US$3.2 million), compared with non-GAAP net income attributable to So-Young International Inc. of RMB9.5 million in the same period of 2023.
Third Quarter 2024 Operational Highlights
- Average mobile MAUs were 1.4 million, compared with 3.1 million in the third quarter of 2023.
- Number of medical service providers subscribing to information services on So-Young's platform was 1,322, compared with 1,397 in the third quarter of 2023.
- Total number of purchasing users through reservation services was 114.9 thousand and the aggregate value of medical aesthetic treatment transactions facilitated by So-Young's platform was RMB346.0 million.
Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, said, "Our third quarter performance beat the high end of our guidance once again, highlighting the resilience of our business. Sales of medical products and maintenance services grew by 18.7% year-over-year, becoming a key growth driver contributing to a year-over-year increase in net income. This underscores the effectiveness of our strategy to stay at the forefront of industry trends by deepening the synergies from our vertical integration and continuously diversifying our offerings. Our clinic network has experienced significant growth. The number of stores has grown to 16 by the end of this quarter, extending our presence into additional major cities. All stores are situated in central business districts, enhancing our market coverage and competitive position. To further scale our offline presence, we are accelerating the deployment of this proven standardized model in other cities nationwide and are exploring franchising opportunities to engage with a wider audience. The reputational strength of our brand and our deep understanding of evolving consumer behavior uniquely position us to develop products that resonate with consumer needs. Sales momentum remains robust, driven by both our well-established products and exciting new launches in collaboration with our supply chain partners. Looking ahead, we are committed to seizing opportunities across the entire medical aesthetics value chain while deepening the integration of our three core businesses to maximize operational efficiency, customer satisfaction, and sustainable growth."
Mr. Hui Zhao, Chief Financial Officer of So-Young, added, "Our third-quarter results reflect our ability to strategically adapt to changing market dynamics. Through disciplined cost management and targeted growth initiatives, we are carefully navigating this challenging market environment while building a solid foundation for future expansion. Encouragingly, our net income and non-GAAP net income attributable to So-Young International Inc. improved significantly, with year-over-year growth rates exceeding 8.9% and 133.1% respectively. Looking ahead, we will leverage our expanding network of clinics and meticulously curated product offerings to address the growing demand for high-quality solutions and services. By maintaining operational efficiency and scalability, we are well-positioned to continue leading the medical aesthetics sector, delivering sustainable growth and long-term value for our shareholders."
[1] This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB7.0176 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on September 30, 2024.
[2] Non-GAAP net income attributable to So-Young International Inc. is defined as net income attributable to So-Young International Inc. excluding share-based compensation expenses attributable to So-Young International Inc. See "Reconciliation of GAAP and Non-GAAP Results" at the end of this press release.
Third Quarter 2024 Financial Results
Revenues
Total revenues were RMB371.8 million (US$53.0 million), a decrease of 3.5% from RMB385.3 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.
- Information services and other revenues were RMB263.0 million (US$37.5 million), a decrease of 8.0% from RMB285.9 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.
- Reservation services revenues were RMB19.6 million (US$2.8 million), a decrease of 18.9% from RMB24.1 million in the same period of 2023. The decrease was primarily due to a decrease in consumer spending through our platform.
- Sales of medical products and maintenance services were RMB89.3 million (US$12.7 million), an increase of 18.7% from RMB75.2 million in the same period of 2023, primarily due to an increase in the order volumes for cosmetic products and medical equipment.
Cost of Revenues
Cost of revenues was RMB142.2 million (US$20.3 million), a decrease of 0.3% from RMB142.6 million in the third quarter of 2023. The decrease was primarily due to a decrease in the cost of services associated with the information services. Cost of revenues included share-based compensation expenses of RMB0.1 million (US$0.0 million), compared with the share-based compensation expenses of RMB0.4 million in the corresponding period of 2023.
- Cost of services and others were RMB98.6 million (US$14.1 million), a decrease of 4.7% from RMB103.5 million in the third quarter of 2023. The decrease was primarily due to a decrease in the cost of services associated with the information services.
- Cost of medical products sold and maintenance services were RMB43.5 million (US$6.2 million), an increase of 11.3% from RMB39.1 million in the third quarter of 2023. The increase was primarily due to an increase in costs associated with the sales of cosmetic products.
Operating Expenses
Total operating expenses were RMB225.0 million (US$32.1 million), a decrease of 8.1% from RMB244.7 million in the third quarter of 2023.
- Sales and marketing expenses were RMB114.9 million (US$16.4 million), a decrease of 20.1% from RMB143.8 million in the third quarter of 2023. The decrease was mainly due to a decrease in expenses associated with branding and user acquisition activities. Sales and marketing expenses included share-based compensation expenses of RMB0.2 million (US$0.0 million), compared with RMB0.5 million in the corresponding period of 2023.
- General and administrative expenses were RMB69.9 million (US$10.0 million), an increase of 39.1% from RMB50.2 million in the third quarter of 2023. The increase was primarily due to an increase in share-based compensation expenses. General and administrative expenses included share-based compensation expenses of RMB1.3 million (US$0.2 million), compared with a reversal of share-based compensation expenses of RMB11.2 million in the corresponding period of 2023.
- Research and development expenses were RMB40.2 million (US$5.7 million), a decrease of 20.6% from RMB50.6 million in the third quarter of 2023. The decrease was primarily attributable to improvements in staff efficiency. Research and development expenses included share-based compensation expenses of RMB0.3 million (US$0.0 million), compared with RMB1.5 million in the corresponding period of 2023.
Income Tax (Expenses)/Benefits
Income tax expenses were RMB2.1 million (US$0.3 million), compared with income tax benefits of RMB2.2 million in the same period of 2023.
Net Income Attributable to So-Young International Inc.
Net income attributable to So-Young International Inc. was RMB20.3 million (US$2.9 million), compared with a net income attributable to So-Young International Inc. of RMB18.3 million in the third quarter of 2023.
Non-GAAP Net Income Attributable to So-Young International Inc.
Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses attributable to So-Young International Inc., was RMB22.2 million (US$3.2 million), compared with RMB9.5 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2023.
Basic and Diluted Earnings per ADS
Basic and diluted earnings per ADS attributable to ordinary shareholders were RMB0.20 (US$0.03) and RMB0.20 (US$0.03), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.18 and RMB0.18, respectively, in the same period of 2023.
Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments
As of September 30, 2024, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,252.6 million (US$178.5 million), compared with RMB1,341.6 million as of December 31, 2023.
Business Outlook
For the fourth quarter of 2024, So-Young expects total revenues to be between RMB350.0 million (US$49.9 million) and RMB370.0 million (US$52.7 million), representing a 10.4% to 5.3% decrease from the same period in 2023. The above outlook is based on the current market conditions and reflects the Company's preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.
Non-GAAP Financial Measures
To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income attributable to So-Young International Inc. by excluding share-based compensation expenses from income/(loss) from operations and net income attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company's operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company's core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company's results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company's performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.
Conference Call Information
So-Young's management will hold an earnings conference call on Wednesday, November 20, 2024, at 7:00 AM U.S. Eastern Time (8:00 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:
International:
+1-412-902-4272
Mainland China:
4001-201203
US:
+1-888-346-8982
Hong Kong:
+852-301-84992
Passcode:
So-Young International Inc.
A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, November 27, 2024. The dial-in details are:
International:
+1-412-317-0088
US:
+1-877-344-7529
Passcode:
2642052
Additionally, a live and archived webcast of this conference call will be available at .
About So-Young International Inc.
So-Young International Inc. (Nasdaq: SY) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young's strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young's strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young's strategies; So-Young's future business development, financial condition and results of operations; So-Young's ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.
For more information, please contact:
So-Young
Investor Relations
Ms. Mona Qiao
Phone: +86-10-8790-2012
E-mail:
Christensen
In China
Ms. Dee Wang
Phone: +86-10-5900-1548
E-mail:
In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email:
SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except for share and per share data)
As of
December 31,
September 30,
September 30,
2023
2024
2024
RMB
RMB
US$
Assets
Current assets:
Cash and cash equivalents
426,119
467,407
66,605
Restricted cash and term deposits
14,695
104,198
14,848
Trade receivables
57,219
106,943
15,239
Inventories
118,924
145,601
20,748
Receivables from online payment platforms
23,158
31,666
4,512
Amounts due from related parties
9,212
10,466
1,491
Term deposits and short-term investments
900,823
681,035
97,047
Prepayment and other current assets
171,774
221,227
31,525
Total current assets
1,721,924
1,768,543
252,015
Non-current assets:
Long-term investments
261,016
287,507
40,969
Intangible assets
145,253
131,641
18,759
Goodwill
540,693
540,693
77,048
Property and equipment, net
116,782
154,572
22,026
Deferred tax assets
78,034
81,057
11,551
Operating lease right-of-use assets
118,408
159,179
22,683
Other non-current assets
232,455
180,628
25,739
Total non-current assets
1,492,641
1,535,277
218,775
Total assets
3,214,565
3,303,820
470,790
Liabilities
Current liabilities:
Short-term borrowings
29,825
89,559
12,762
Taxes payable
56,894
53,639
7,643
Contract liabilities
103,374
94,747
13,501
Salary and welfare payables
86,290
84,927
12,102
Amounts due to related parties
388
146
21
Accrued expenses and other current liabilities
233,913
244,721
34,873
Operating lease liabilities-current
29,739
40,398
5,757
Total current liabilities
540,423
608,137
86,659
Non-current liabilities:
Operating lease liabilities-non current
86,210
124,915
17,800
Deferred tax liabilities
25,082
20,780
2,961
Other non-current liabilities
1,536
1,607
229
Total non-current liabilities
112,828
147,302
20,990
Total liabilities
653,251
755,439
107,649
SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Continued)
(Amounts in thousands, except for share and per share data)
Shareholders'equity:
Treasury stock
(358,453)
(369,907)
(52,711)
Class A ordinary shares (US$0.0005 par value; 750,000,000
shares authorized as of December 31, 2023 and September
30, 2024; 73,688,044 and 63,422,436 shares issued and
outstanding as of December 31, 2023, 77,634,580 and
66,170,882 shares issued and outstanding as of September
30, 2024, respectively)
238
252
36
Class B ordinary shares (US$ 0.0005 par value; 20,000,000
shares authorized as of December 31, 2023 and September
30, 2024; 12,000,000 shares issued and outstanding as of
December 31, 2023 and September 30, 2024)
37
37
5
Additional paid-in capital
3,080,433
3,067,567
437,125
Statutory reserves
33,855
33,855
4,824
Accumulated deficit
(330,166)
(312,117)
(44,476)
Accumulated other comprehensive income
18,185
8,858
1,262
Total So-Young International Inc. shareholders' equity
2,444,129
2,428,545
346,065
Non-controlling interests
117,185
119,836
17,076
Total shareholders' equity
2,561,314
2,548,381
363,141
Total liabilities and shareholders'equity
3,214,565
3,303,820
470,790
SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except for share and per share data)
For the Three Months Ended
For the Nine Months Ended
September30, 2023
September
30, 2024
September
30, 2024
September
30, 2023
September
30, 2024
September
30, 2024
RMB
RMB
US$
RMB
RMB
US$
Revenues:
Information services and others
285,937
262,988
37,475
795,100
750,952
107,010
Reservation services
24,140
19,567
2,788
80,724
64,987
9,261
Sales of medical products and maintenance services
75,217
89,270
12,721
231,639
281,548
40,120
Total revenues
385,294
371,825
52,984
1,107,463
1,097,487
156,391
Cost of revenues:
Cost of services and others
(103,484)
(98,620)
(14,053)
(291,503)
(274,695)
(39,144)
Cost of medical products sold and maintenance services
(39,119)
(43,548)
(6,206)
(115,199)
(139,839)
(19,927)
Total cost of revenues
(142,603)
(142,168)
(20,259)
(406,702)
(414,534)
(59,071)
Gross profit
242,691
229,657
32,725
700,761
682,953
97,320
Operating expenses:
Sales and marketing expenses
(143,844)
(114,884)
(16,371)
(394,276)
(360,448)
(51,363)
General and administrative expenses
(50,242)
(69,901)
(9,961)
(204,097)
(225,653)
(32,155)
Research and development expenses
(50,597)
(40,188)
(5,727)
(158,531)
(122,277)
(17,424)
Total operating expenses
(244,683)
(224,973)
(32,059)
(756,904)
(708,378)
(100,942)
(Loss)/Incomefrom operations
(1,992)
4,684
666
(56,143)
(25,425)
(3,622)
Other income/(expenses):
Investment income, net
647
510
73
10,869
3,397
484
Interest income, net
12,130
14,239
2,029
38,023
38,270
5,453
Exchange gains/(losses)
103
465
66
(1,051)
875
125
Share of losses of equity method investee
(3,822)
(3,873)
(552)
(10,692)
(11,602)
(1,653)
Others, net
9,887
6,915
985
18,474
12,234
1,743
Income/(Loss)before tax
16,953
22,940
3,267
(520)
17,749
2,530
Income tax benefits/(expenses)
2,191
(2,097)
(299)
7,240
3,031
432
Net income
19,144
20,843
2,968
6,720
20,780
2,962
Net income attributable to noncontrolling interests
(839)
(495)
(71)
(2,941)
(2,731)
(389)
Netincomeattributable to So-Young International Inc.
18,305
20,348
2,897
3,779
18,049
2,573
SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued)
(Amounts in thousands, except for share and per share data)
For the Three Months Ended
For the Nine Months Ended
September
30, 2023
September
30, 2024
September
30, 2024
September
30, 2023
September
30, 2024
September
30, 2024
RMB
RMB
US$
RMB
RMB
US$
Net earningsper ordinary share
Net earnings per ordinary share attributable to ordinary shareholder - basic
0.24
0.26
0.04
0.05
0.23
0.03
Net earnings per ordinary share attributable to ordinary shareholder - diluted
0.24
0.26
0.04
0.05
0.23
0.03
Net earnings per ADS attributable to ordinary shareholders - basic (13 ADS
represents 10 Class A ordinary shares)
0.18
0.20
0.03
0.04
0.18
0.03
Net earnings per ADS attributable to ordinary shareholders - diluted (13 ADS
represents 10 Class A ordinary shares)
0.18
0.20
0.03
0.04
0.18
0.03
Weighted average number of ordinary shares used in computing earnings/(loss)
per share, basic*
76,842,709
79,493,819
79,493,819
78,001,149
79,544,066
79,544,066
Weighted average number of ordinary shares used in computing earnings/(loss)
per share, diluted*
77,210,781
79,708,518
79,708,518
78,402,636
79,810,666
79,810,666
Share-based compensation expenses included in:
Cost of services and others
(418)
(81)
(12)
(1,635)
(255)
(36)
Sales and marketing expenses
(533)
(183)
(26)
(2,850)
(420)
(60)
General and administrative expenses
11,164
(1,328)
(189)
(10,400)
(27,796)
(3,961)
Research and development expenses
(1,454)
(309)
(44)
(3,636)
(1,969)
(281)
* Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.
SO-YOUNG INTERNATIONAL INC.
Reconciliation of GAAP and Non-GAAP Results
(Amounts in thousands, except for share and per share data)
For the Three Months Ended
For the Nine Months Ended
September
30, 2023
September30, 2024
September
30, 2024
September
30, 2023
September
30, 2024
September
30, 2024
RMB
RMB
US$
RMB
RMB
US$
GAAP (loss)/incomefrom operations
(1,992)
4,684
666
(56,143)
(25,425)
(3,622)
Add back: Share-based compensation expenses
(8,759)
1,901
271
18,521
30,440
4,338
Non-GAAP (loss)/incomefrom operations
(10,751)
6,585
937
(37,622)
5,015
716
GAAP net incomeattributable to So-Young International Inc.
18,305
20,348
2,897
3,779
18,049
2,573
Add back: Share-based compensation expenses
(8,759)
1,901
271
18,521
30,440
4,338
Non-GAAP net incomeattributable to So-Young International Inc.
9,546
22,249
3,168
22,300
48,489
6,911